logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Economic evaluation of rotavirus vaccinations in finland : Randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine.

    Article - En anglais

    Fulltext.

    The cost-benefit ratio of tetravalent rhesus rotavirus vaccine (RRV-TV) in Finland for prevention of rotavirus gastroenteritis was assessed in a randomized, double-blind, placebo-controlled trial.

    Costs related to vaccination, side effects, and gastroenteritis were identified.

    Children received RRV-TV (n=1,191) or placebo (n=1,207) at 2,3, and 5 months of age with other infant vaccinations.

    Prospective follow-up averaged 1.0 years per child.

    An intention-to-treat analysis was performed from the perspective of society.

    Nine cases of severe rotavirus gastroenteritis occurred in the RRV-TV group, versus 100 in the placebo group (P<. 0001) ; mean cost per vaccinated child was 4 Finnish marks (FIM) in the RRV-TV group, versus 203 FIM in the placebo group.

    Side effects with related costs occurred after 11% and 7% of doses in the RRV-TV group and placebo group, respectively (P<. 001) ; mean cost per child was 89 FIM vs. 75 FIM.

    The break-even cost (i.e., net benefit, excluding cost of vaccine) of RRV-TV in prevention of severe rotavirus gastroenteritis was 109 FIM (U.S. $19.60) per child.

    Mots-clés Pascal : Rotavirus, Reoviridae, Virus, Gastroentérite, Immunoprophylaxie, Vaccin associé, Vaccination, Finlande, Europe, Prévention, Analyse avantage coût, Efficacité, Toxicité, Effet secondaire, Enfant, Homme, Virose, Infection, Economie santé, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie

    Mots-clés Pascal anglais : Rotavirus, Reoviridae, Virus, Gastroenteritis, Immunoprophylaxis, Mixed vaccine, Vaccination, Finland, Europe, Prevention, Cost benefit analysis, Efficiency, Toxicity, Secondary effect, Child, Human, Viral disease, Infection, Health economy, Digestive diseases, Gastric disease, Intestinal disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0400987

    Code Inist : 002B05C02F. Création : 25/01/1999.